Shots:
- Galderma signed an agreement to acquire 100% of ZO Skin Health for an enterprise value of $1.5B in an all-cash transaction, expanding its dermatological skincare portfolio alongside Cetaphil and Alastin
- ZO Skin Health offers more than 40 skincare products and serves over 16,500 physician, medical spa, and online accounts across more than 40 countries. The brand recorded ~$330M in net sales in the 12 months ended June 2026
- The acquisition will combine ZO Skin Health’s daily skincare regimens with Alastin’s regenerative skincare portfolio. Closing is expected in Q4’26 or early 2027, subject to regulatory approvals and customary conditions; the acquisition is expected to be Core EPS neutral in the first full year following closing
Ref: Galderma | Image: Galderma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
